CPIG
RLMD icon

Chicago Partners Investment Group’s Relmada Therapeutics RLMD Stock Holding History

Chicago Partners Investment Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,310
Closed -$56.5K – 683
2022
Q4 		$56.5K Buy
+14,310
New +$126K ﹤0.01% 628

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Chicago Partners Investment Group's RLMD Position: Q1 2023 in Review

Chicago Partners Investment Group sold out of Relmada Therapeutics (RLMD) in Q1 2023, closing a stake of 14,310 shares — an estimated $56.5K sold.

Chicago Partners Investment Group first reported a position in RLMD in Q4 2022 and held it in 1 quarter. The position peaked at $56.5K in Q4 2022. 91 funds tracked by Wall St. Rank hold RLMD as of Q1 2023.

  • Chicago Partners Investment Group reported no remaining Relmada Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Chicago Partners Investment Group sold 14,310 Relmada Therapeutics shares in Q1 2023, an estimated $56.5K.
  • Chicago Partners Investment Group first reported a position in Relmada Therapeutics in Q4 2022 and held it in 1 quarter.
  • Chicago Partners Investment Group's Relmada Therapeutics position peaked at $56.5K in Q4 2022.
  • 91 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2023.

Based on Chicago Partners Investment Group's 13F filing for Q1 2023, filed 26 Apr 2023.